• Go to navigation
  • Go to content
AstraZeneca Clinical Trials

Astrazeneca Worldwide

  • AstraZeneca Websites
AstraZeneca US

Main navigation

  • Home
  • Therapy Areas
    • Oncology/Infection
    • Cardiovascular
    • Gastrointestinal
    • Neuroscience
    • Respiratory/Inflammation
  • Drug Products
    • All Drug Products
  • Diseases & Conditions
    • All Diseases and Conditions
  • Glossary
  • Contact Us
  • Disclosure Commitment

You are here

  • Home
  • Therapy Areas

  • Cardiovascular

The following trials provide information to treat various types of cardiovascular diseases, both for ongoing and completed clinical trials.  For more information on this therapy area please click here.

There are a number of ways to help you find trial information.  By using these filters you can find (i) recruiting status, (ii) therapy area, (iii) product and/or (iv) phase of drug development.  You can use one or all filters to identify your specific needs.

When a trial completes the results are reported here no later than one year after completion – this is why you may sometimes find that a Report is unavailable when you are searching through ‘closed’ trials.

  • Expand All
  • Collapse All
  • Pages
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next
  • expand Dapagliflozin Effect on Cardiovascular Events A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes
    Study Id
    D1693C00001
    Disease
    myocardial infarction
    Drug Name
    dapagliflozin
    Study Name
    D1693C00001
    Recruiting Status
    Open
    Protocol Status
    Not Available
    Report Status
    Not Available
  • expand A multicenter, single arm, cohort study to evaluate the Efficacy and Safety of saxagliptin 5mg, once daily for 24 weeks, in patients with type 2 diabetes mellitus who are treatment naïve or who have inadequate glycaemic control on metformin alone
    Disease
    diabetes mellitus, diabetes type 2
    Drug Name
    Onglyza, saxagliptin
    Study Name
    SUNSHINE
    Recruiting Status
    Open
    Protocol Status
    Not Available
    Report Status
    Not Available
  • expand A Randomized, Open-Label, Multiple Dose, Crossover, Multiple Center Study of the Antiplatelet Effects of Ticagrelor versus Clopidogrel in African American Patients with Stable Coronary Artery Disease
    Study Id
    Brilinta (AZD6140)
    Disease
    coronary artery disease
    Drug Name
    AZD6140
    Study Name
    D5130L00013
    Recruiting Status
    Open
    Protocol Status
    Not Available
    Report Status
    Not Available
  • expand A Randomized, Open-Label, Multiple Dose, Crossover, Multiple Center Study of the Antiplatelet Effects of Ticagrelor versus Clopidogrel in Hispanic Patients with Stable Coronary Artery Disease
    Study Id
    Brilinta (AZD6140)
    Disease
    coronary artery disease
    Drug Name
    AZD6140
    Study Name
    D5130L00012
    Recruiting Status
    Open
    Protocol Status
    Not Available
    Report Status
    Not Available
  • expand A open label, randomized, crossover and potential parallel, single dose study of ticagrelor 180 mg and acetylsalicylic acid (ASA) in healthy volunteers followed by autologous in vivo platelet transfusion to determine the effects of platelet supplementation on the reversibility of platelet inhibition
    Study Id
    D5130C00079
    Disease
    blood clot
    Drug Name
    Brilinta
    Study Name
    D5130C00079
    Recruiting Status
    Open
    Protocol Status
    Not Available
    Report Status
    Not Available
  • expand A Non-Interventional Study To Evaluate Diabetes Related Quality Of Life, Frequency And Impact Of Hypoglycemia In Type 2 Diabetes Patients On Pharmacotherapy (INSIGHT)
    Study Id
    NIS-CIN-XXX-2011/3
    Disease
    diabetes mellitus, diabetes type 2
    Drug Name
    Onglyza
    Recruiting Status
    Open
    Protocol Status
    Not Available
    Report Status
    Not Available
  • expand A Randomized, Double-blind, Parallel Group, Multicentre Phase IIIb Study to Compare Ticagrelor With Clopidogrel Treatment on the Risk of Cardiovascular Death, Myocardial Infarction and Ischemic Stroke in Patients With Established Peripheral Artery Disease (EUCLID Examining Use of tiCagreLor In paD)
    Study Id
    D5135C00001
    Disease
    myocardial infarction
    Drug Name
    Brilinta
    Study Name
    D5135C00001
    Recruiting Status
    Open
    Protocol Status
    Not Available
    Report Status
    Not Available
  • expand OPtimal Type 2 dIabetes Management Including benchmarking and Standard treatment in CEEMEA
    Study Id
    NIS-CME-XXX-2012/1
    Disease
    diabetes type 2
    Study Name
    OPTIMISE
    Recruiting Status
    Open
    Protocol Status
    Not Available
    Report Status
    Not Available
  • expand A randomized, open-label, multiple-center, parallel group study to compare the platelet inhibition with VerifyNow assay of ticagrelor versus clopidogrel in troponin negative Acute Coronary Syndrome (ACS) subjects undergoing Ad Hoc percutaneous coronary intervention (PCI)
    Study Id
    D5130L00014
    Disease
    acute coronary syndrome
    Drug Name
    Brilinta
    Study Name
    D5130L00014
    Recruiting Status
    Open
    Protocol Status
    Not Available
    Report Status
    Not Available
  • expand A Study to derive normative distribution of CIMT and to determine its cOrrelation with cardiovascular Risk factors in asymptomatic nationwidE Indian population. (SCORE India)
    Study Id
    NIS-CIN-XXX-2011/2
    Disease
    cardiovascular diseases
    Study Name
    NIS-CIN-XXX-2011/2
    Recruiting Status
    Open
    Protocol Status
    Not Available
    Report Status
    Not Available
  • Pages
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next
  • Expand All
  • Collapse All

Page tools

  • Print
  • Bookmark this page

Legal notices

  • Legal notice
  • Privacy policy
  • © AstraZeneca 2013